Twist Bioscience Corporation

NasdaqGS:TWST Stock Report

Market Cap: US$8.0b

Twist Bioscience Valuation

Is TWST undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TWST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: TWST ($125.52) is trading below our estimate of future cash flow value ($200.23)

Significantly Below Future Cash Flow Value: TWST is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TWST?

Key metric: As TWST is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TWST. This is calculated by dividing TWST's market cap by their current revenue.
What is TWST's PS Ratio?
PS Ratio18.2x
SalesUS$431.80m
Market CapUS$8.03b

Price to Sales Ratio vs Peers

How does TWST's PS Ratio compare to its peers?

The above table shows the PS ratio for TWST vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.6x
PTGX Protagonist Therapeutics
33.5x17.02%US$9.4b
IONS Ionis Pharmaceuticals
10.7x28.16%US$9.4b
PTCT PTC Therapeutics
5.6x13.61%US$5.7b
ALKS Alkermes
4.6x9.89%US$7.6b
TWST Twist Bioscience
18.2x17.07%US$8.0b

Price-To-Sales vs Peers: TWST is expensive based on its Price-To-Sales Ratio (18.2x) compared to the peer average (13.5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does TWST's PS Ratio compare vs other companies in the US Biotechs Industry?

119 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
3.1x2.60%US$31.40b
BMRN BioMarin Pharmaceutical
3.7x10.32%US$12.51b
LEGN Legend Biotech
3x15.43%US$3.97b
BCRX BioCryst Pharmaceuticals
2.4x7.50%US$2.32b
TWST 18.2xIndustry Avg. 12.9xNo. of Companies119PS01632486480+
119 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TWST is expensive based on its Price-To-Sales Ratio (18.2x) compared to the US Biotechs industry average (12.9x).

Price to Sales Ratio vs Fair Ratio

What is TWST's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TWST PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.2x
Fair PS Ratio6.5x

Price-To-Sales vs Fair Ratio: TWST is expensive based on its Price-To-Sales Ratio (18.2x) compared to the estimated Fair Price-To-Sales Ratio (6.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TWST forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$125.52
US$106.25
-15.35%
30.45%US$148.00US$36.00n/a12
Sep ’27US$132.06
US$105.30
-20.26%
22.70%US$120.00US$36.00n/a10
Aug ’27US$91.55
US$92.50
+1.04%
27.35%US$120.00US$36.00n/a10
Jul ’27US$102.25
US$74.10
-27.53%
22.84%US$95.00US$36.00n/a10
Jun ’27US$67.86
US$64.38
-5.14%
19.01%US$80.00US$36.00n/a8
May ’27US$60.40
US$55.00
-8.94%
17.10%US$75.00US$36.00n/a9
Apr ’27US$49.54
US$50.44
+1.83%
12.30%US$58.00US$36.00n/a9
Mar ’27US$46.92
US$49.89
+6.33%
12.01%US$58.00US$36.00n/a9
Feb ’27US$41.07
US$41.50
+1.05%
12.11%US$50.00US$33.00n/a8
Jan ’27US$31.72
US$35.89
+13.14%
9.60%US$42.00US$32.00n/a9
Dec ’26US$29.86
US$35.63
+19.31%
9.82%US$42.00US$32.00n/a8
Nov ’26US$32.89
US$39.43
+19.88%
12.56%US$50.00US$35.00n/a7
Oct ’26US$29.26
US$42.14
+44.03%
12.65%US$50.00US$35.00n/a7
Sep ’26US$26.97
US$40.00
+48.31%
18.87%US$50.00US$25.00US$132.068
Aug ’26US$33.68
US$48.42
+43.76%
17.40%US$62.00US$33.00US$91.5510
Jul ’26US$36.75
US$48.42
+31.75%
17.40%US$62.00US$33.00US$102.2510
Jun ’26US$29.30
US$48.38
+65.12%
16.60%US$62.00US$33.00US$67.8611
May ’26US$37.71
US$50.74
+34.56%
13.91%US$62.00US$40.00US$60.4011
Apr ’26US$38.94
US$54.38
+39.65%
11.00%US$62.00US$40.00US$49.5411
Mar ’26US$38.82
US$55.11
+41.95%
10.69%US$62.00US$40.00US$46.9211
Feb ’26US$52.37
US$52.14
-0.44%
12.59%US$60.00US$35.00US$41.0711
Jan ’26US$46.47
US$51.81
+11.49%
12.89%US$60.00US$35.00US$31.7211
Dec ’25US$49.18
US$50.49
+2.66%
12.03%US$58.00US$35.00US$29.8610
Nov ’25US$41.57
US$50.39
+21.22%
12.66%US$58.00US$35.00US$32.8910
Oct ’25US$43.40
US$50.79
+17.03%
15.05%US$65.00US$35.00US$29.2610
Sep ’25US$43.24
US$50.39
+16.54%
14.81%US$65.00US$35.00US$26.9710
US$106.25
Fair Value
18.1% overvalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 21:50
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Twist Bioscience Corporation is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BambergerBaird
Catherine Ramsey SchulteBaird
Luke SergottBarclays